Evidence map›Paper›PMID 39852709›Full record

ArticleNanomaterials (Basel, Switzerland)2025

Calcium Phosphate Nanoparticles Functionalized with a Cardio-Specific Peptide.

Federica Mancini, Lorenzo Degli Esposti, Alessio Adamiano, Jessica Modica, Daniele Catalucci, Dora Mehn, Otmar Geiss, Michele Iafisco

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Federica ManciniInstitute of Science, Technology and Sustainability for Ceramics (ISSMC), National Research Council (CNR), 48018 Faenza, Italy.
Lorenzo Degli EspostiInstitute of Science, Technology and Sustainability for Ceramics (ISSMC), National Research Council (CNR), 48018 Faenza, Italy.ORCID 0000-0002-6596-560X
Alessio AdamianoInstitute of Science, Technology and Sustainability for Ceramics (ISSMC), National Research Council (CNR), 48018 Faenza, Italy.ORCID 0000-0002-2077-0411
Jessica ModicaIRCCS Humanitas Research Hospital, Humanitas Cardio Center, 20089 Rozzano, Italy.ORCID 0000-0002-4986-8009
Daniele CatalucciIRCCS Humanitas Research Hospital, Humanitas Cardio Center, 20089 Rozzano, Italy.ORCID 0000-0001-7041-6114
Dora MehnEuropean Commission, Joint Research Center (JRC), 21027 Ispra, Italy.ORCID 0000-0003-3482-2996
Otmar GeissEuropean Commission, Joint Research Center (JRC), 21027 Ispra, Italy.ORCID 0000-0002-5371-3798
Michele IafiscoInstitute of Science, Technology and Sustainability for Ceramics (ISSMC), National Research Council (CNR), 48018 Faenza, Italy.ORCID 0000-0002-7813-8347

Funding

Joint Research Centre 36689/2Ministero dell'università e della ricerca 202085RFNY
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, highliting the urgent need for new therapeutic strategies. Peptide-based therapies have demonstrated significant potential for treating CVDs; however, their clinical application is hindered by their limited stability in physiological fluids. To overcome this challenge, an effective drug delivery system is essential to protect and efficiently transport peptides to their intended targets. This study introduces two distinct strategies for loading a cardio-specific mimetic peptide (MP), previously designed to modulate L-type calcium channel function in cardiomyocytes, onto calcium phosphate nanoparticles (CaP NPs). MP-loaded CaP NPs were prepared by two different wet precipitation syntheses, one of which involved the use of sodium polyacrylate as a templating agent. Characterization of MP-loaded CaP NPs showed that their crystallinity, size, surface charge, and morphology could be tuned by adjusting the synthesis parameters. In vitro tests on cardiac cells confirmed that both types of MP-loaded CaP NPs are biocompatible with HL-1 cardiomyocytes and restored intracellular calcium flux under stressed conditions, highlighting their therapeutic potential. These results pave the way for further optimization of CaP NP formulations and suggest their potential as a viable nanomaterial for CVD treatment.

Indexed as

calcium phosphatecardiovascular diseasesdrug deliverynanoparticlestherapeutic peptides

Identifiers

PMID39852709
PMCPMC11767714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.